Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL

समान संसाधन

• HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
  द्वारा: Jin, Xin, और अन्य
  प्रकाशित: (2019)
• Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
  द्वारा: Cao, Yaqing, और अन्य
  प्रकाशित: (2019)
• Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
  द्वारा: Zhu, Haibo, और अन्य
  प्रकाशित: (2021)
• Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
  द्वारा: Meng Zhang, और अन्य
  प्रकाशित: (2025-01-01)
• Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
  द्वारा: Wang, Jia, और अन्य
  प्रकाशित: (2020)